| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 13,6 k € | +4.0% | 13,0 k € | -10.3% | 14,6 k € | -12.8% | 16,7 k € | +5.1% | 15,9 k € | +73.5% | 9,2 k € | -28.3% | 12,8 k € | -26.2% | 17,3 k € | -6.0% | 18,4 k € | +43.5% | 12,8 k € | -98.8% | 1,1 M € | -14.1% | 1,2 M € | +10.3% | 1,1 M € | -23.9% | 1,5 M € | +3846.2% | 37,1 k € | +17.3% | 31,7 k € | -38.8% | 51,7 k € | -95.0% | 1,0 M € | |
| EBITDA | 12,3 k € | +4.1% | 11,8 k € | -11.4% | 13,3 k € | -14.5% | 15,6 k € | +5.4% | 14,8 k € | +80.4% | 8,2 k € | -30.2% | 11,7 k € | -27.9% | 16,3 k € | -5.3% | 17,2 k € | +47.8% | 11,6 k € | -98.9% | 1,1 M € | -10.7% | 1,2 M € | +10.7% | 1,1 M € | -24.4% | 1,4 M € | +3832.5% | 36,1 k € | +17.9% | 30,7 k € | -40.1% | 51,2 k € | -95.1% | 1,0 M € | |
| Operating profit | 10,7 k € | +4.7% | 10,3 k € | -22.7% | 13,3 k € | -14.7% | 15,6 k € | +5.4% | 14,8 k € | +108.3% | 7,1 k € | -30.1% | 10,1 k € | -30.9% | 14,7 k € | -12.0% | 16,7 k € | +48.8% | 11,2 k € | -98.9% | 1,1 M € | -10.7% | 1,2 M € | +10.7% | 1,1 M € | -24.3% | 1,4 M € | +4198.6% | 33,0 k € | +17.7% | 28,1 k € | -40.2% | 46,9 k € | -95.4% | 1,0 M € | |
| Profit/loss | 0,4 € | +109.0% | -4,8 € | -241.8% | 3,4 € | +148.1% | -7,0 € | -163.1% | 11,1 € | +105.4% | -203,6 € | -3415.3% | 6,1 € | -96.9% | 196,6 € | +7235.1% | 2,7 € | -83.5% | 16,2 € | -100.0% | 1,1 M € | -10.9% | 1,2 M € | +10.6% | 1,1 M € | -25.1% | 1,4 M € | +4549.6% | 30,6 k € | +9.7% | 27,9 k € | -23.0% | 36,2 k € | -95.0% | 723,5 k € | |
| Equity | 40,6 k € | +7.1% | 38,0 k € | +1.2% | 37,5 k € | +10.6% | 33,9 k € | +5.6% | 32,1 k € | -15.3% | 38,0 k € | +2.5% | 37,0 k € | -6.8% | 39,7 k € | +3.5% | 38,4 k € | +4.3% | 36,8 k € | -3.5% | 38,2 k € | +4.2% | 36,6 k € | +4.4% | 35,1 k € | +5.2% | 33,4 k € | -95.3% | 716,7 k € | +4.5% | 686,2 k € | +4.2% | 658,3 k € | +5.8% | 622,1 k € | |
| Total assets | 3,3 M € | +12.5% | 3,0 M € | +84.9% | 1,6 M € | +40.4% | 1,1 M € | -20.1% | 1,4 M € | +1.5% | 1,4 M € | -3.5% | 1,5 M € | +13.0% | 1,3 M € | -1.9% | 1,3 M € | -16.2% | 1,6 M € | +41.4% | 1,1 M € | -14.8% | 1,3 M € | +3.4% | 1,3 M € | -14.9% | 1,5 M € | -9.7% | 1,6 M € | -7.7% | 1,8 M € | +27.0% | 1,4 M € | +33.0% | 1,1 M € | |
| Cash | 1,3 M € | +95.2% | 653,4 k € | +829.5% | 70,3 k € | +28.9% | 54,5 k € | -25.5% | 73,2 k € | +53.5% | 47,7 k € | -85.9% | 338,1 k € | +1582.5% | 20,1 k € | -74.4% | 78,5 k € | -76.1% | 329,1 k € | +568.8% | 49,2 k € | -83.5% | 298,1 k € | +238.1% | 88,2 k € | -69.8% | 292,0 k € | -35.5% | 453,1 k € | -43.9% | 808,1 k € | +142.8% | 332,8 k € | +261.0% | 92,2 k € | |
| Debts | 3,3 M € | +12.5% | 2,9 M € | +86.9% | 1,6 M € | +41.4% | 1,1 M € | -20.7% | 1,4 M € | +2.0% | 1,4 M € | -3.7% | 1,4 M € | +13.6% | 1,3 M € | -2.0% | 1,3 M € | -16.7% | 1,5 M € | +43.0% | 1,1 M € | -15.3% | 1,3 M € | +3.4% | 1,2 M € | -15.4% | 1,4 M € | +56.6% | 925,3 k € | -15.3% | 1,1 M € | +47.1% | 742,5 k € | +72.1% | 431,4 k € | |
| Staff | — | — | — | — | — | — | — | — | — | — | — | 0,8 | 1 | — | — | — | — | — | ||||||||||||||||||
Cooperative society · Namur · incorporated on 12/04/2007
Cooperative society profitable and well capitalised. Cash position rising (+95.2%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Service d'Oncologie Radiothérapie Médecine Nucléaire is a Cooperative society incorporated in 2007. Its main activity is: Other human health activities. Its registered office is in Namur.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette